Drug Trial Radar · NCT02152761
Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery
Last checked: Nov 19, 2026Latest source record: Aug 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
251
Actual
Start
Sep 16, 2014
Primary completion
May 14, 2018
Study completion Oct 25, 2018
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jun 2, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to assess if bimagrumab is safe and effective in patients with muscle wasting (atrophy) after hip fracture surgery.
Conditions
- Muscle Wasting (Atrophy) After Hip Fracture Surgery
Interventions
bimagrumabDrug
Bimagrumab was administered as intravenous infusion starting on Day 1 until week 20.
placeboOther
Matching placebo was administered as intravenous infusion starting on Day 1 until week 20.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Total Lean Body Mass Measured by DXA (Dual-energy X-ray Absorptiometry) at Weeks 12 and 24Time frame: baseline, weeks 12 and 24
Locations
53 sites in 19 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
El Cajon, California
Novartis Investigative Site
Denver, Colorado
Novartis Investigative Site
Gainesville, Georgia
Novartis Investigative Site
Rochester, Minnesota
Novartis Investigative Site
New York, New York
Novartis Investigative Site
Ciudad Autonoma de Bs As, Argentina
Novartis Investigative Site
Bedford Park, South Australia, Australia
Novartis Investigative Site
Graz, Austria
Novartis Investigative Site
Bruges, Belgium
Novartis Investigative Site
Genk, Belgium
Novartis Investigative Site
Ghent, Belgium
Novartis Investigative Site
Santiago, Chile
Novartis Investigative Site
Barranquilla, Colombia
Novartis Investigative Site
Cali, Valle del Cauca Department, Colombia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Brno, Czech Republic, Czechia
Novartis Investigative Site
Hradec Králové, Czech Republic, Czechia
Novartis Investigative Site
Pardubice, Czech Republic, Czechia
Novartis Investigative Site
Pilsen, Czech Republic, Czechia
Novartis Investigative Site
Prague, Czech Republic, Czechia
Novartis Investigative Site
Lille, France
Novartis Investigative Site
Montpellier, France
Novartis Investigative Site
Bad Abbach, Germany
Novartis Investigative Site
Dresden, Germany
Novartis Investigative Site
Magdeburg, Germany
Novartis Investigative Site
Würzburg, Germany
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Hatvan, Hungary
Novartis Investigative Site
Nishinomiya, Hyōgo, Japan
Novartis Investigative Site
Kamakura, Kanagawa, Japan
Novartis Investigative Site
Kochi, Kochi, Japan
Novartis Investigative Site
Kumamoto, Kumamoto, Japan
Novartis Investigative Site
Okayama, Okayama-ken, Japan
Novartis Investigative Site
Toyama, Toyama, Japan
Novartis Investigative Site
Aguascalientes, Mexico
Novartis Investigative Site
San Luis Potosí City, Mexico
Novartis Investigative Site
Saint Petersburg, Russia
Novartis Investigative Site
Saint Petersburg, Russia
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.